Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With A...
Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
About this item
Full title
Author / Creator
Publisher
Boston, USA: Wiley Periodicals, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Boston, USA: Wiley Periodicals, Inc
Subjects
More information
Scope and Contents
Contents
Objective
Previous analyses of pooled DISCOVER‐1 and DISCOVER‐2 data through Week 24 showed significantly higher rates of dactylitis resolution in patients treated with guselkumab compared with placebo. Here, we investigate associations between dactylitis resolution and other outcomes through 1 year.
Methods
Patients were randomized 1:1:1...
Alternative Titles
Full title
Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b952304b10bc473db051a75aae6f707d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b952304b10bc473db051a75aae6f707d
Other Identifiers
ISSN
2578-5745
E-ISSN
2578-5745
DOI
10.1002/acr2.11537
